BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24472154)

  • 1. Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer.
    Garland SM; Brown DR
    Expert Opin Biol Ther; 2014 Apr; 14(4):527-34. PubMed ID: 24472154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Australian experience with the human papillomavirus vaccine.
    Garland SM
    Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
    Paavonen J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.
    Mandic A
    J BUON; 2012; 17(3):422-7. PubMed ID: 23033276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
    Maver PJ; Poljak M
    Vaccine; 2018 Aug; 36(36):5416-5423. PubMed ID: 28801154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer.
    Palmer KE; Jenson AB; Kouokam JC; Lasnik AB; Ghim SJ
    Exp Mol Pathol; 2009 Jun; 86(3):224-33. PubMed ID: 19454268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV vaccines to prevent cervical cancer and genital warts: an update.
    Dochez C; Bogers JJ; Verhelst R; Rees H
    Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus vaccine: the beginning of the end for cervical cancer.
    Bornstein J
    Isr Med Assoc J; 2007 Mar; 9(3):156-8. PubMed ID: 17402325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.